Evidence map›Paper›PMID 41368037›Full record

ArticleBMJ neurology open2025

Patient and physician perceptions of the burden of tardive dyskinesia: an international survey.

Craig Chepke, Aviva Peyser Levin, Amy Yang, Suzanne Reed, Erwan Berjonneau, Perrine Le Calvé, Marc Tian, Shoshana Reshef, Dahbia Horchi, Kasim Tugrul Ustundag and 1 more

Abstract read
In one paragraph

Article in BMJ neurology open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Tardive blepharospasm.Journal of neurology · 2026
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Craig ChepkeExcel Psychiatric Associates, Huntersville, North Carolina, USA.ORCID https://orcid.org/0000-0002-4873-4770
Aviva Peyser LevinTeva Pharmaceutical Industries Ltd, Tel Aviv, Israel.
Amy YangTeva Branded Pharmaceutical Products R&D LLC, West Chester, Pennsylvania, USA.
Suzanne ReedOracle Life Sciences, Paris, France.
Erwan BerjonneauOracle Life Sciences, Paris, France.
Perrine Le CalvéOracle Life Sciences, Paris, France.
Marc TianTeva Branded Pharmaceutical Products R&D LLC, West Chester, Pennsylvania, USA.
Shoshana ReshefTeva Branded Pharmaceutical Products R&D LLC, Parsippany, New Jersey, USA.
Dahbia HorchiOracle Life Sciences, Paris, France.
Kasim Tugrul UstundagTeva Pharmaceutical Industries Ltd, Istanbul, Turkey.
Rinat RibalovTeva Pharmaceutical Industries Ltd, Tel Aviv, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Tardive dyskinesia (TD) negatively affects overall quality of life (QoL) and day-to-day activities, and perceptions of these effects and their impact may vary between cultures and societies, or providers and patients. Physicians' discernments of this burden could improve efforts to detect, diagnose and treat TD. This study assessed TD impact from both patients' and physicians' perspectives in multiple countries. Methods: Patients who self-reported a physician diagnosis of TD and schizophrenia, schizoaffective disorder, bipolar disorder or major depressive disorder exhibiting 'extra, irregular movements' and physicians (neurologists or psychiatrists) who treated ≥3 patients with TD in the prior 2 years participated in individual 20-minute online surveys. Participating physicians and patients were not linked. Results: Patients (N=435) and physicians (N=340) were recruited from Australia, Brazil, China, South Korea and Israel. Most patients (84.8%) and physicians (87.6%) reported a moderate/high or moderate to very strong impact of TD symptoms on QoL. Patients and physicians noted substantial negative impacts of TD on patients' daily lives, emotional and psychological states, and social activities. Many patients reported that TD often/always affected their treatment compliance for their underlying psychiatric condition (28.7%); that TD worsened their underlying psychiatric condition (24.8%), or that they developed other psychiatric conditions (46.9%); most physicians similarly perceived a moderate/very strong impact of TD in these areas (75.3%, 70.9% and 77.6%, respectively). Conclusions: Patients and physicians across participating countries agreed that TD substantially impacts patient QoL and can undermine psychiatric stability by worsening underlying psychiatric conditions and treatment adherence. Also, physicians saw the physical and emotional/psychological/social effects of TD as being almost equally impactful, whereas patients generally reported a greater impact of emotional/psychological/social effects than physical effects. The differences between the levels of importance that patients and physicians assigned to these areas of TD impact highlight the need for more thorough communication between them.

Indexed as

CLINICAL NEUROLOGYMOVEMENT DISORDERS

Identifiers

PMID41368037
PMCPMC12684145

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.